Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Dec;60(6):809–814. doi: 10.1038/bjc.1989.371

Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators.

M Sehested 1, P B Jensen 1, T Skovsgaard 1, N Bindslev 1, E J Demant 1, E Friche 1, L Vindeløv 1
PMCID: PMC2247270  PMID: 2605092

Abstract

The multidrug resistance (MDR) phenotype is presumed to be mostly dependent on changes in the resistant cell plasma membrane, notably the emergence of a 170 kDa glycoprotein called P-glycoprotein, which facilitate increased drug efflux. We have previously demonstrated that ATP-enhanced binding of vincristine (VCR) to plasma membrane vesicles is much greater in MDR than in wild type cells. The present study has shown that VCR binding to MDR Ehrlich ascites tumour cell plasma membrane vesicles is inhibited 50% most efficiently by quinidine (0.5 microM) followed by verapamil (4.1 microM) and trifluoperazine (23.2 microM). This is the reverse order of the effect on whole cells where a ranking of efficiency in terms of enhancement of VCR accumulation, inhibition of VCR efflux, DNA perturbation and modulation of resistance in a clonogenic assay, was trifluoperazine greater than or equal to verapamil much greater than quinidine. The detergent Tween 80 inhibited VCR binding to plasma membrane vesicles at 0.001% v/v which agreed with the level which modulated resistance and increased VCR accumulation in whole cells. No effect was observed on daunorubicin binding to MDR plasma membrane vesicles after incubation with either Tween 80 (up to 0.1% v/v) or verapamil (up to 25 microM). We conclude that the effect of a modulating drug in reversing resistance to VCR correlates with its ability to raise intracellular VCR levels but not with its capability to inhibit VCR binding to the plasma membrane. Thus, enhancement of VCR accumulation in MDR cells is hardly solely due to competition for a drug binding site on P-glycoprotein. Furthermore, the lack of a demonstrable effect on daunorubicin binding to the plasma membrane by modulators points to transport mechanisms which do not utilise specific drug binding to the plasma membrane.

Full text

PDF
809

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama S., Cornwell M. M., Kuwano M., Pastan I., Gottesman M. M. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol. 1988 Feb;33(2):144–147. [PubMed] [Google Scholar]
  2. Alabaster O., Cassidy M. Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo. J Natl Cancer Inst. 1978 Mar;60(3):649–652. doi: 10.1093/jnci/60.3.649. [DOI] [PubMed] [Google Scholar]
  3. Beck W. T. The cell biology of multiple drug resistance. Biochem Pharmacol. 1987 Sep 15;36(18):2879–2887. doi: 10.1016/0006-2952(87)90198-5. [DOI] [PubMed] [Google Scholar]
  4. Bindslev N., Wright E. M. Histidyl residues at the active site of the Na/succinate co-transporter in rabbit renal brush borders. J Membr Biol. 1984;81(2):159–170. doi: 10.1007/BF01868980. [DOI] [PubMed] [Google Scholar]
  5. Bradley G., Juranka P. F., Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta. 1988 Aug 3;948(1):87–128. doi: 10.1016/0304-419x(88)90006-6. [DOI] [PubMed] [Google Scholar]
  6. Cornwell M. M., Safa A. R., Felsted R. L., Gottesman M. M., Pastan I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci U S A. 1986 Jun;83(11):3847–3850. doi: 10.1073/pnas.83.11.3847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta. 1973 Oct 25;323(3):466–483. doi: 10.1016/0005-2736(73)90191-0. [DOI] [PubMed] [Google Scholar]
  8. Dano K. Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. Cancer Chemother Rep. 1972 Dec;56(6):701–708. [PubMed] [Google Scholar]
  9. Dano K. Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor. Cancer Chemother Rep. 1971 Apr;55(2):133–141. [PubMed] [Google Scholar]
  10. Friche E., Skovsgaard T., Nissen N. I. Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol. 1987;19(1):35–39. doi: 10.1007/BF00296252. [DOI] [PubMed] [Google Scholar]
  11. Ganapathi R., Yen A., Grabowski D., Schmidt H., Turinic R., Valenzuela R. Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells. Br J Cancer. 1986 Apr;53(4):561–566. doi: 10.1038/bjc.1986.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gerlach J. H., Endicott J. A., Juranka P. F., Henderson G., Sarangi F., Deuchars K. L., Ling V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature. 1986 Dec 4;324(6096):485–489. doi: 10.1038/324485a0. [DOI] [PubMed] [Google Scholar]
  13. Gottesman M. M., Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 1988 Sep 5;263(25):12163–12166. [PubMed] [Google Scholar]
  14. Horio M., Gottesman M. M., Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci U S A. 1988 May;85(10):3580–3584. doi: 10.1073/pnas.85.10.3580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Klohs W. D., Steinkampf R. W. The effect of lysosomotropic agents and secretory inhibitors on anthracycline retention and activity in multiple drug-resistant cells. Mol Pharmacol. 1988 Aug;34(2):180–185. [PubMed] [Google Scholar]
  16. Naito M., Hamada H., Tsuruo T. ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem. 1988 Aug 25;263(24):11887–11891. [PubMed] [Google Scholar]
  17. Naito M., Tsuruo T. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res. 1989 Mar 15;49(6):1452–1455. [PubMed] [Google Scholar]
  18. Riehm H., Biedler J. L. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res. 1972 Jun;32(6):1195–1200. [PubMed] [Google Scholar]
  19. Roed H., Christensen I. B., Vindeløv L. L., Spang-Thomsen M., Hansen H. H. Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines. Eur J Cancer Clin Oncol. 1987 Feb;23(2):177–186. doi: 10.1016/0277-5379(87)90012-5. [DOI] [PubMed] [Google Scholar]
  20. Roed H., Vindelov L. L., Christensen I. J., Spang-Thomsen M., Hansen H. H. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. Cancer Chemother Pharmacol. 1987;19(1):16–20. doi: 10.1007/BF00296248. [DOI] [PubMed] [Google Scholar]
  21. Safa A. R., Glover C. J., Meyers M. B., Biedler J. L., Felsted R. L. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem. 1986 May 15;261(14):6137–6140. [PubMed] [Google Scholar]
  22. Safa A. R. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7187–7191. doi: 10.1073/pnas.85.19.7187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Seeber S., Osieka R., Schmidt C. G., Achterrath W., Crooke S. T. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res. 1982 Nov;42(11):4719–4725. [PubMed] [Google Scholar]
  24. Sehested M., Skovsgaard T., van Deurs B., Winther-Nielsen H. Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer. 1987 Dec;56(6):747–751. doi: 10.1038/bjc.1987.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Skovsgaard T. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 1978 Dec;38(12):4722–4727. [PubMed] [Google Scholar]
  26. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 1978 Jun;38(6):1785–1791. [PubMed] [Google Scholar]
  27. Spitzer E., Böhmer F. D., Grosse R. Identification of Ca2+-pump-related phosphoprotein in plasma membrane vesicles of Ehrlich ascites carcinoma cells. Biochim Biophys Acta. 1983 Feb 9;728(1):50–58. doi: 10.1016/0005-2736(83)90435-2. [DOI] [PubMed] [Google Scholar]
  28. Tsuruo T., Iida H., Kitatani Y., Yokota K., Tsukagoshi S., Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res. 1984 Oct;44(10):4303–4307. [PubMed] [Google Scholar]
  29. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 May;41(5):1967–1972. [PubMed] [Google Scholar]
  30. Vindeløv L. L., Christensen I. J., Keiding N., Spang-Thomsen M., Nissen N. I. Long-term storage of samples for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):317–322. doi: 10.1002/cyto.990030502. [DOI] [PubMed] [Google Scholar]
  31. Vindeløv L. L., Christensen I. J., Nissen N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983 Mar;3(5):323–327. doi: 10.1002/cyto.990030503. [DOI] [PubMed] [Google Scholar]
  32. Zamora J. M., Pearce H. L., Beck W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol. 1988 Apr;33(4):454–462. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES